Silexion Therapeutics (NASDAQ: SLXN) reported a net loss of $2.5 million, or $13.70 per basic and diluted share, for the third quarter ended September 30, 2026. The company reported cash and cash equivalents of $4.8 million at quarter-end.
The clinical-stage biotechnology company said the first patient was dosed in its Phase 2/3 SIL204 trial for locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center.
- Third-quarter research and development expense was $1.3 million, down from $2.2 million a year earlier.
- General and administrative expense was $1.4 million, compared with $1.1 million in the prior-year quarter.
- Nine-month net loss was $8.8 million, compared with $7.5 million for the first nine months of 2025.
- During the quarter, Silexion completed a $2.5 million public offering, a $0.84 million warrant inducement transaction and $1.9 million in at-the-market share sales.
- The company effected a 1-for-24 reverse share split on November 10, 2026.
$SLXNW Hedge Fund Activity
We have seen 3 institutional investors add shares of $SLXNW stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF MONTREAL /CAN/ added 956,966 shares (+inf%) to their portfolio in Q3 2026, for an estimated $4,880
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 92,073 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,799
- SABA CAPITAL MANAGEMENT, L.P. removed 11,937 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $362
- GOLDMAN SACHS GROUP INC added 1,609 shares (+1.3%) to their portfolio in Q2 2026, for an estimated $48
- CLEAR STREET GROUP INC. removed 600 shares (-0.3%) from their portfolio in Q2 2026, for an estimated $18
- DUPONT CAPITAL MANAGEMENT CORP added 0 shares (+0.0%) to their portfolio in Q3 2026, for an estimated $0
- POLAR ASSET MANAGEMENT PARTNERS INC. added 0 shares (+0.0%) to their portfolio in Q2 2026, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.